Mereo BioPharma

85 articles about Mereo BioPharma

• 

  Roche's Latest Checkpoint Target Shows Promise for Lung Cancer

  12/10/2021

  Roche announced promising results from the Phase II CITYSCAPE study of tiragolumab plus Tecentriq compared to Tecentriq alone as a treatment for PD-L1-positive metastatic NSCLC. 
• 

  Clinical Catch-Up: November 29-December 3

  12/6/2021

  Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.

• Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors

  11/30/2021

  Mereo BioPharma Group plc today reported promising interim efficacy, safety, and biomarker data on patients from ACTIVATE, a Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with nivolumab in select recurrent advanced / metastatic solid tumors.

• Mereo BioPharma to Present at Two Upcoming Investor Conferences

  11/9/2021

  Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will present at two upcoming investor conferences: Jefferies London Healthcare Conference In-person Fireside Chat, Wednesday, November 17 at 10:00 a.m. Greenwich Mean Time

• Data from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting

  11/4/2021

  Mereo BioPharma Group plc announced that data from an investigator-sponsored study of alvelestat in patients with Bronchiolitis Obliterans Syndrome following hematopoietic stem cell transplantation will be shared in a poster presentation at the 2021 American Society of Hematology Annual Meeting, being held December 11-14, 2021 in Atlanta, Georgia and virtually.

• Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment

  10/13/2021

  Mereo BioPharma Group plc, “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, the Osteogenesis Imperfecta Federation Europe and the Osteogenesis Imperfecta Foundation announced completion of enrollment in the largest global gathering of data to date about the impact that OI has on people with OI, their families and caregivers.

• 

  BioSpace Movers & Shakers, Sept. 24

  9/24/2021

  Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• Mereo BioPharma to Participate in Three Upcoming Investor Conferences

  9/9/2021

  Mereo BioPharma Group plc today announced senior management’s participation in three upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference 1x1 meetings, September 13 – 14, 2021

• Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

  6/2/2021

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced positive data from an interim analysis of an investigator-initiated study of alvelestat in patients with Bronchiolitis Obliterans Syndrome following hematopoietic stem cell transplantation.

• Mereo BioPharma to Participate in a Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference

  5/27/2021

  Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Thursday, June 3, 2021 at 8:00am Eastern Time.

• Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021

  5/4/2021

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced it will host a virtual R&D day on Thursday, May 13, 2021 to review the Company’s etigilimab program, highlighting studies in ovarian cancer including Clear-cell ovarian cancer, Cervical cancer and Sarcoma.

• Mereo BioPharma to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference

  2/18/2021

  Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00am Eastern Time.

• Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

  2/12/2021

  Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the closing of its previously announced underwritten public offering of 39,675,000 American Depositary Shares (“ADSs”), at a public offering price of $2.90 per ADS, which includes 5,175,000 additional ADSs issued upon the exercise in full of the underwriters’ option to

• Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares

  2/9/2021

  Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering.

• Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development

  11/23/2020

  Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announces the appointment of Suba Krishnan, M.D. as Senior Vice President of Clinical Development, effective December 7, 2020.

• Mereo BioPharma to Hold Virtual R&D Day on Tuesday, November 24, 2020

  11/16/2020

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced it will host a virtual R&D day on Tuesday, November 24, to review the Company’s key pipeline programs including etigilimab for solid tumors and alvelestat for alpha-1 antitrypsin deficiency and COVID-19 respiratory disease.

• Mereo BioPharma to Present at the Stifel 2020 Virtual Healthcare Conference

  11/10/2020

  Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am Eastern Time. A live audio webcast of the presentation can be accessed through the Inve

• 

  BioSpace Movers & Shakers, Oct. 23

  10/23/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Global Roundup, Oct. 22

  10/22/2020

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Mereo BioPharma Appoints Christine Fox as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs

  10/20/2020

  Mereo BioPharma Group plc, a clinical stage biopharmaceutical company focused on oncology and rare diseases, announced the appointment of Christine Fox, CPA, as Chief Financial Officer and Heidi Petersen as Senior Vice President, Regulatory Affairs.